Pharma Update

Roche delivered consistent growth through biosimilar erosion Successful diversification of our portfolio Roche From three oncology assets driving ~50% of sales in 2012... ... to a diversified portfolio with assets that span multiple therapeutic areas today Diagnostics CHF 10.2bn 21%2 9% 9% Pharmaceuticals 9% CHF 35.2bn AHR1 52% Diagnostics CHF 17.7bn 15%3 8% 16% Pharmaceuticals 17% CHF 45.2bn 30% 14%4 AHR1 2022 2012 AHR1 Oncology Infectious diseases Neuroscience Immunology Hemophilia A Other Diagnostics 1 AHR: Avastin, Herceptin, Rituxan; 2 Includes Metabolism (5%), Ophthalmology (4%), Respiratory (3%), Cardiovascular (3%) and others (6%); 3 Includes Infectious Diseases (5%), Ophthalmology (4%) and others (7%); 4 Reduction in AHR sales due to Loss of Exclusivity and biosimilar competition. Source: Roche Annual Report 2012, Roche Annual Report 2022, Roche Finance Report 2022 14 14

View entire presentation